Reaction
Cytomegalovirus Hepatitis reporting signals
As of the last recalculation, Cytomegalovirus Hepatitis appears in 349 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is GANCICLOVIR SODIUM (PRR 151.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ganciclovir Sodium | 25 | 151.7 | 152.0 |
| Ganciclovir | 24 | 150.1 | 150.5 |
| Valganciclovir Hydrochloride Powder, | 22 | 114.7 | 114.9 |
| Valganciclovir | 30 | 103.7 | 103.9 |
| Valganciclovir Hydrochloride | 30 | 103.7 | 103.9 |
| Basiliximab | 15 | 79.4 | 79.5 |
| Pegaspargase | 12 | 60.5 | 60.6 |
| Phenobarbital | 14 | 60.0 | 60.0 |
| Anakinra | 15 | 56.3 | 56.4 |
| Mesna Injection | 7 | 51.5 | 51.6 |
| Mesna | 7 | 50.6 | 50.6 |
| Bendamustine Hydrochloride | 9 | 46.0 | 46.0 |
| Fludarabine Phosphate | 26 | 42.5 | 42.6 |
| Phenytoin | 14 | 41.6 | 41.7 |
| Mercaptopurine | 11 | 39.0 | 39.1 |
| Bendamustine Hcl | 8 | 31.5 | 31.5 |
| Polatuzumab Vedotin | 5 | 31.0 | 31.0 |
| Obinutuzumab | 6 | 22.1 | 22.1 |
| Daptomycin | 3 | 19.6 | 19.6 |